CC
TBPH icon

Clearline Capital’s Theravance Biopharma TBPH Stock Holding History

Clearline Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-577,800
Closed -$4.28M – 173
2021
Q3 		$4.28M Buy
+577,800
New +$6.46M 0.4% 54
2019
Q3 		– Sell
-37,258
Closed -$608K – 64
2019
Q2 		$608K Buy
+37,258
New +$755K 0.3% 41
2015
Q4 		– Sell
-516,804
Closed -$5.68M – 63
2015
Q3 		$5.68M Buy
516,804
+28,812
+6% +$367K 0.96% 26
2015
Q2 		$6.35M Buy
487,992
+244,286
+100% +$3.79M 0.88% 29
2015
Q1 		$4.23M Sell
243,706
-6,844
-3% -$125K 0.63% 41
2014
Q4 		$3.74M Buy
+250,550
New +$4.36M 0.58% 43

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Clearline Capital's TBPH Position: Q4 2021 in Review

Clearline Capital sold out of Theravance Biopharma (TBPH) in Q4 2021, closing a stake of 577,800 shares — an estimated $4.28M sold.

Clearline Capital first reported a position in TBPH in Q4 2014 and held it in 6 quarters. The position peaked at $6.35M in Q2 2015. 116 funds tracked by Wall St. Rank hold TBPH as of Q4 2021.

  • Clearline Capital reported no remaining Theravance Biopharma position as of Q4 2021 after selling out during the quarter.
  • Clearline Capital sold 577,800 Theravance Biopharma shares in Q4 2021, an estimated $4.28M.
  • Clearline Capital first reported a position in Theravance Biopharma in Q4 2014 and held it in 6 quarters.
  • Clearline Capital's Theravance Biopharma position peaked at $6.35M in Q2 2015.
  • 116 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2021.

Based on Clearline Capital's 13F filing for Q4 2021, filed 14 Feb 2022.